Last reviewed · How we verify
NCT07402382
Effects of Amylopectin Chromium Blend on Whole-Body Protein Kinetics and Glucose in Peri/Post-Menopausal Women
NA trial testing Amylopectin-chromium blend in Glucose Monitoring, Continuous in 60 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Nutrition 21, Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 60 |
| Start date | 1 November 2025 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Amylopectin-chromium blend
- Concentrated Amylopectin-chromium blend
- Placebo
Conditions studied
- Glucose Monitoring, Continuous — all drugs for Glucose Monitoring, Continuous →
- Whole Body Protein Metabolism — all drugs for Whole Body Protein Metabolism →
- Peri-menopausal Women — all drugs for Peri-menopausal Women →
- Post-menopause — all drugs for Post-menopause →
Sponsor
Nutrition 21, Inc. — full company profile →
Who can join
Adults 40 to 70, female only, with Glucose Monitoring, Continuous or Whole Body Protein Metabolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to better understand how an amylopectin chromium blend may influence whole body protein balance in women during midlife, when hormonal changes can adversely affect protein metabolism and muscle maintenance. Continuous glucose monitoring will also be used to assess glycemic control over a 24-hour period. The main questions the study aims to answer are: * Does the use of an amylopectin chromium blend in peri- and post-menopausal women help to support positive protein balance * Can the affect be achieved using a concentrated dose Researchers will compare the nutritional supplement to a placebo (amylopectin alone) to see if the amylopectin chromium blend can promote positive protein balance. A concentrated dose of the supplement will also be evaluated for comparative effectiveness. Participants will: * Consume the nutritional supplement (standard or concentrated dose) or placebo acutely after a short resistance exercise bout * Complete four in-person visits, including the single-day intervention Results from this research may help guide future nutritional strategies to support healthy aging, muscle function, and overall metabolic health.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07402382
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07402382 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nutrition 21, Inc.
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07402382.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing